EU Commission authorises a third vaccine against influenza A (H1N1)

The European Commission has authorised the use of Celvapan® (Baxter) as a vaccine against influenza A (H1N1). The authorisation follows last week's recommendation by the European Medicines Agency (EMEA) to the European Commission to grant a marketing authorisation for the vaccine.

Apart from Celvapan®, the European Commission has previously authorised the use of Focetria® (Novartis) and Pandemrix® (GlaxoSmithKline) for influenza A (H1N1). Pandemrix® will be used in Denmark.

For further information, please contact Head of Department, Marianne Orholm, on tel.: +45 4488 9740.

Danish Medicines Agency, 8 October 2009